Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Werkzaamheid en veiligheid van depemokimab vergeleken met mepolizumab bij volwassenen met recidiverende of refractaire eosinofiele granulomatose met polyangiitis (EGPA) (OCEAN)

17 november 2026 bijgewerkt door: GlaxoSmithKline

Een 52 weken durende, gerandomiseerde, dubbelblinde, dubbeldummy, parallelle groep, multicenter, non-inferioriteitsstudie om de werkzaamheid en veiligheid van depemokimab te onderzoeken in vergelijking met mepolizumab bij volwassenen met recidiverende of refractaire eosinofiele granulomatose met polyangiitis (EGPA ) Standard of Care (SoC)-therapie ontvangen

This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

163

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • La Plata, Argentinië, B1900
        • GSK Investigational Site
      • San Miguel de Tucumán, Argentinië, T4000
        • GSK Investigational Site
      • Santo André, Brazilië, 09060-870
        • GSK Investigational Site
      • São Paulo, Brazilië, 4023900
        • GSK Investigational Site
    • Ontario
      • Toronto, Ontario, Canada, M5T 3A9
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M5T 3L9
        • GSK Investigational Site
      • Beijing, China, 100005
        • GSK Investigational Site
      • Guangzhou, China, 510163
        • GSK Investigational Site
      • Hefei, China, 230001
        • GSK Investigational Site
      • Nanjing, China, 210006
        • GSK Investigational Site
      • Qingdao, China, 266071
        • GSK Investigational Site
      • Shanghai, China, 200032
        • GSK Investigational Site
      • Shenzhen, China, 518020
        • GSK Investigational Site
      • Wenzhou, China, 325000
        • GSK Investigational Site
      • Freiburg im Breisgau, Duitsland, 79106
        • GSK Investigational Site
      • Minden, Duitsland, 32429
        • GSK Investigational Site
      • Brest, Frankrijk, 29609
        • GSK Investigational Site
      • La Roche-sur-Yon, Frankrijk, 85925
        • GSK Investigational Site
      • Nantes, Frankrijk, 44093
        • GSK Investigational Site
      • Paris, Frankrijk, 75014
        • GSK Investigational Site
      • Budapest, Hongarije, 1023
        • GSK Investigational Site
      • Ramat Gan, Israël, 52621
        • GSK Investigational Site
      • Bari, Italië, 70124
        • GSK Investigational Site
      • Brescia, Italië, 25123
        • GSK Investigational Site
      • Florence, Italië, 50134
        • GSK Investigational Site
      • Milan, Italië, 20132
        • GSK Investigational Site
      • Milan, Italië, 20162
        • GSK Investigational Site
      • Pavia, Italië, 27100
        • GSK Investigational Site
      • Pisa, Italië, 56126
        • GSK Investigational Site
      • Roma, Italië, 00128
        • GSK Investigational Site
      • Torrette AN, Italië, 60126
        • GSK Investigational Site
      • Treviso, Italië, 31100
        • GSK Investigational Site
      • Kanagawa, Japan, 252-0392
        • GSK Investigational Site
      • Kanagawa, Japan, 247-8533
        • GSK Investigational Site
      • Saitama, Japan, 350-8550
        • GSK Investigational Site
      • Tokyo, Japan, 181-8611
        • GSK Investigational Site
      • Tokyo, Japan, 162-8666
        • GSK Investigational Site
      • Groningen, Nederland, 9713 GZ
        • GSK Investigational Site
      • Leiden, Nederland, 2333 ZA
        • GSK Investigational Site
    • Styria
      • Graz, Styria, Oostenrijk, 8036
        • GSK Investigational Site
      • Gdansk, Polen, 80-952
        • GSK Investigational Site
      • Lodz, Polen, 90-153
        • GSK Investigational Site
      • Warsaw, Polen, 01-138
        • GSK Investigational Site
      • Lisbon, Portugal, 1649-035
        • GSK Investigational Site
      • Porto, Portugal, 4099-001
        • GSK Investigational Site
      • Barcelona, Spanje, 08036
        • GSK Investigational Site
      • Barcelona, Spanje, 08035
        • GSK Investigational Site
      • Granada, Spanje, 18014
        • GSK Investigational Site
      • Pamplona, Spanje, 31008
        • GSK Investigational Site
      • Zaragoza, Spanje, 50009
        • GSK Investigational Site
      • Birmingham, Verenigd Koninkrijk, B15 2GW
        • GSK Investigational Site
      • London, Verenigd Koninkrijk, SE1 7EH
        • GSK Investigational Site
    • Cambridgeshire
      • Cambridge, Cambridgeshire, Verenigd Koninkrijk, CB2 2QQ
        • GSK Investigational Site
    • Colorado
      • Denver, Colorado, Verenigde Staten, 80206
        • GSK Investigational Site
    • Florida
      • Gainesville, Florida, Verenigde Staten, 32610
        • GSK Investigational Site
    • Minnesota
      • Rochester, Minnesota, Verenigde Staten, 55905-0001
        • GSK Investigational Site
    • New York
      • New York, New York, Verenigde Staten, 10021-4823
        • GSK Investigational Site
    • North Carolina
      • Charlotte, North Carolina, Verenigde Staten, 28211
        • GSK Investigational Site
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15261
        • GSK Investigational Site
      • Gwangju, Zuid -Korea, 61469
        • GSK Investigational Site
      • Seoul, Zuid -Korea, 06351
        • GSK Investigational Site
      • Seoul, Zuid -Korea, 06591
        • GSK Investigational Site
      • Seoul, Zuid -Korea, 05505
        • GSK Investigational Site
    • Seoul Teugbyeolsi
      • Seoul, Seoul Teugbyeolsi, Zuid -Korea, 3080
        • GSK Investigational Site
      • Malmö, Zweden, SE-205 02
        • GSK Investigational Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Participant (male or female) must be 18 years of age or older at the time of signing the informed consent.
  • Participants who are >=40 kilogram at Screening Visit 1.
  • Participants with a documented diagnosis of EGPA for at least 6 months based on the history or presence of: asthma plus eosinophilia defined as >1.0*10^9/Liter (L) and/or >10 percentage (%) of leucocytes plus at least 2 of the following additional features of EGPA: a biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation, neuropathy, mono or poly (motor deficit or nerve conduction abnormality), pulmonary infiltrates, non-fixed, sino-nasal abnormality, cardiomyopathy (established by echocardiography or magnetic resonance imaging), glomerulonephritis (hematuria, red cell casts, proteinuria), alveolar hemorrhage (by bronchoalveolar lavage), palpable purpura, anti-neutrophil cytoplasmic antibodies positive Myeloperoxidase or Proteinase 3.
  • History of relapsing OR refractory disease.
  • Participants must be on a stable dose of oral prednisolone or prednisone of >=7.5 mg/day (but not >50 mg/day) or equivalent for at least 4 weeks prior to Baseline (Visit 2).
  • If participants receiving immunosuppressive therapy (excluding cyclophosphamide) the dosage must be stable for the 4 weeks prior to Baseline (Visit 2) and during the study.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non-childbearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of <1%.
  • Capable of giving signed informed consent

Exclusion Criteria:

  • Participants diagnosed with granulomatosis with polyangiitis; previously known as Wegener's granulomatosis or microscopic polyangiitis.
  • Participants with organ-threatening EGPA as per EULAR criteria,
  • Imminently life-threatening EGPA disease within 3 months prior to Screening (Visit 1).
  • A current malignancy or previous history of cancer in remission for less than 12 months prior to Screening.
  • Participants with alanine aminotransferase >2*upper limit of normal (ULN) or if participant is on background methotrexate or azathioprine >3*ULN, aspartate aminotransferase >2*ULN or if participant is on background methotrexate or azathioprine >3*ULN, alkaline phosphatase >=2.0*ULN, total bilirubin >1.5*ULN (isolated bilirubin >1.5*ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%), Cirrhosis or current unstable liver or biliary disease per investigator assessment.
  • Participants who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment.
  • Participants who have known, pre-existing, clinically significant system abnormalities that are not associated with EGPA and are uncontrolled with standard treatment.
  • Clinically significant abnormality in the hematological, biochemical or urinalysis screen at Visit 1.
  • Chronic or ongoing active infectious disease requiring systemic treatment.
  • Participants with a known, pre-existing parasitic infestation within 6 months prior to Screening Visit 1.
  • A known immunodeficiency (e.g., human immunodeficiency virus [HIV]).
  • Participants that, according to the investigator's medical judgment, are likely to have active coronavirus disease 2019 (COVID-19) infection. Participants with known COVID-19 positive contacts within the past 14 days must be excluded for at least 14 days following the exposure during which the participant must remain symptom-free.
  • Participants with a known allergy or intolerance to a monoclonal antibody or biologic therapy or any of the excipients of the investigational products.
  • Participants who have a previous documented failure with anti-Interleukin-5 /Interleukin-5 receptor therapy (e.g., mepolizumab, reslizumab, benralizumab). Participants who have received monoclonal antibodies (mAb) and who have not undergone the required washout periods, prior to Visit 1.
  • Participants receiving any of the following: Oral corticosteroids: Participant requires an oral corticosteroid dose of >50 mg/day prednisolone/prednisone in the 4-week period prior to Baseline (Visit 2), Intravenous (IV), intramuscular or subcutaneous (SC) corticosteroids in the 4-week period prior to Baseline (Visit 2), Omalizumab within 130 days prior to Screening (Visit 1), Cyclophosphamide (CYC): oral CYC within 4 weeks prior to Baseline (Visit 2) and IV CYC within 3 weeks prior to Baseline (Visit 2), if their total white blood cells is >=4*10^9/L (measured using the local laboratory if necessary), Rituximab within 12 months prior to Screening (Visit 1); in addition, the Participant must have shown recovery of peripheral B-cell count to within the normal range, Tezepelumab and Dupilumab with a washout period of 5 half-lives prior to Screening Visit 1, IV or SC immunoglobulin within 6 months prior to Screening (Visit 1); For China and Japan only within 12 weeks prior to Screening (Visit 1), Interferon-alpha within 6 months prior to Screening Visit 1, Anti-tumor necrosis factor therapy within 12 weeks prior to Screening Visit 1, Anti-CD52 (alemtuzumab) within 6 months prior to Screening Visit 1.
  • Participants with QT interval corrected for heart rate according to Fridericia's formula (QTcF) >=450 milliseconds (msec) or QTcF >=480 msec for participants with Bundle Branch Block in the 12-lead ECG central over-read from at Screening Visit 1.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Deelnemers die depemokimab + placebo-matching mepolizumab kregen

Depemokimab will be administered

Placebo matching to mepolizumab will be administered.

Actieve vergelijker: Deelnemers die mepolizumab + placebo-matching depemokimab kregen

Mepolizumab will be administered

Placebo matching to depemokimab will be administered.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of participants with remission (Birmingham Vasculitis Activity Score [BVAS] =0 and a dose of oral corticosteroid [OCS] less than or equal to [<=] 4 milligram [mg] per day)
Tijdsspanne: Up to Week 52

Participants must be in remission at both Weeks 36 and 52.

Up to Week 52

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Aantal deelnemers dat remissie bereikte volgens de definitie van de European League against Rheumatism (EULAR) (BVAS = 0 en OCS <=7,5 mg/dag) in week 36 en week 52
Tijdsspanne: In week 36 en 52
In week 36 en 52
Aantal deelnemers met remissie (BVAS=0 en OCS <=7,5 mg/dag) binnen de eerste 24 weken met aanhoudende remissie tot week 52
Tijdsspanne: Tot week 52
Tot week 52
Aantal deelnemers dat remissie bereikte (BVAS = 0 en OCS ≤ 4 mg/dag) binnen de eerste 24 weken met voortgezette remissie tot week 52
Tijdsspanne: Tot week 52
Tot week 52
Number of participants in each category of accrued duration of remission
Tijdsspanne: Up to Week 52

Total accrued duration of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <= 4 mg/day over the 52-week intervention period. The accrued duration was categorized into zero, >0 to <12 weeks, 12 to <24 weeks, 24 to <36 weeks or more than or equal to (>=) 36 weeks.

Up to Week 52
Number of participants with total accrued duration of remission
Tijdsspanne: Up to Week 52

Total accrued duration of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <= 4 mg/day over the 52-week intervention period.

Up to Week 52
Time to first EGPA relapse
Tijdsspanne: Up to Week 52

The time to first EGPA relapse will be calculated from the date of first dose of study intervention and start date of the EGPA relapse.

Up to Week 52
Number of participants receiving in each category of mean OCS dose during the last 4 weeks of study treatment period (Weeks 49 to 52)
Tijdsspanne: Weeks 49 to 52

Number of participants receiving the mean OCS dose (categorized as 0, >0 to <=4, >4 to <=7.5 or >7.5 mg/day) will be assessed during the last 4 weeks of the study treatment period (Weeks 49 to 52).

Weeks 49 to 52
Number of participants in each category of accrued duration of remission according to the EULAR definition of remission (BVAS = 0 plus OCS <=7.5 mg/day) over 52-week intervention period
Tijdsspanne: Up to Week 52

Total accrued duration of remission according to the EULAR definition of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <=7.5 mg/day over the 52 week intervention period categorized as zero weeks; >0 to <12 weeks; 12 to <24 weeks; 24 to <36 weeks or >= 36 weeks.

Up to Week 52
Number of participants with total accrued duration of remission according to the EULAR definition of remission
Tijdsspanne: Up to Week 52

Total accrued duration of remission according to the EULAR definition of remission is the accrued number of weeks where BVAS=0 plus OCS <=7.5 mg/day over the 52-week intervention period.

Up to Week 52

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: GSK Clinical Trials, GlaxoSmithKline

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

14 juli 2022

Primaire voltooiing (Werkelijk)

6 oktober 2026

Studie voltooiing (Werkelijk)

27 oktober 2026

Studieregistratiedata

Eerst ingediend

28 februari 2022

Eerst ingediend dat voldeed aan de QC-criteria

28 februari 2022

Eerst geplaatst (Werkelijk)

3 maart 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

17 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

IPD for this study will be made available via the Clinical Study Data Request site.

IPD-tijdsbestek voor delen

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

IPD-toegangscriteria voor delen

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF
  • MVO

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren